APA (7th ed.) Citation

W, Z., L, L., M, M., M, B., N, T., K, I., . . . M, A. (2025). Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild-type Acute Myeloid Leukemias. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(14), 3033. https://doi.org/10.1158/1078-0432.CCR-24-2764

Chicago Style (17th ed.) Citation

W, Zhang, et al. "Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild-type Acute Myeloid Leukemias." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 31, no. 14 (2025): 3033. https://doi.org/10.1158/1078-0432.CCR-24-2764.

MLA (9th ed.) Citation

W, Zhang, et al. "Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild-type Acute Myeloid Leukemias." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 31, no. 14, 2025, p. 3033, https://doi.org/10.1158/1078-0432.CCR-24-2764.